AI Article Synopsis
- - Ruxolitinib is effective in modifying the immune response, which can increase the risk of severe infections.
- - Despite the infection risks, ruxolitinib appears to be a practical treatment option for those with polycythemia vera and myelofibrosis.
- - This treatment strategy is particularly relevant for patients who have undergone liver transplantation.
Article Abstract
Although ruxolitinib contributes to immunomodulation and can lead to severe infections, it seems a feasible treatment strategy for patients with polycythemia vera and myelofibrosis after liver transplantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418679 | PMC |
| http://dx.doi.org/10.1002/ccr3.4782 | DOI Listing |
Publication Analysis
Top Keywords
polycythemia vera
8
vera myelofibrosis
8
liver transplantation
8
ruxolitinib treatment
4
treatment polycythemia
4
myelofibrosis patients
4
patients liver
4
transplantation ruxolitinib
4
ruxolitinib contributes
4
contributes immunomodulation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!